Assessment of Interleukin 17 in Egyptian Systemic Lupus Erythematosus Patients as a Biomarker in Disease Activity.

IF 1.2 Q4 RHEUMATOLOGY Current rheumatology reviews Pub Date : 2024-01-01 DOI:10.2174/0115733971282065240123075748

Mervat Behiry, Mary Wadie, Nagwa Abdelghaffar Mohamed, Rania Farid, Hala Ramadan

{"title":"Assessment of Interleukin 17 in Egyptian Systemic Lupus Erythematosus Patients as a Biomarker in Disease Activity.","authors":"Mervat Behiry, Mary Wadie, Nagwa Abdelghaffar Mohamed, Rania Farid, Hala Ramadan","doi":"10.2174/0115733971282065240123075748","DOIUrl":null,"url":null,"abstract":"Introduction: Systemic lupus erythematosus (SLE) is a chronic idiopathic systemic autoimmune disorder with dysregulation of adaptive and innate immune systems. Interleukin (IL)-17 is the prototypical pro-inflammatory cytokine of T helper 17 (Th17) cells. Therefore, it contributes to the pathogenesis of human SLE.Aim: The aim of the research paper was the evaluation of IL-17 level as a biomarker in the SLE cohort and its relation to disease activity and analysis of IL-17 concentration in patients with lupus nephritis and non-lupus nephritis.Methods: The research enrolled 45 SLE patients according to Systemic Lupus International Collaborating Clinics Classification Criteria (SLICC), and age and sex-matched. The patients underwent full history, clinical examination, laboratory investigation, and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) calculation.Results: The mean age ± SD of the participants equaled 32 ± 11 years, and serum IL-17 in SLE cases was statistically significantly high (p < 0.001). No statistically significant correlations were reported between disease activity according to SLEDAI and IL-17. In addition, a statistically significant positive correlation was reported between IL-17 and ESR, and a high statistically significant negative correlation was reported between IL-17 and C3 and C4 (P < 0.001). A statistically significant positive correlation was reported between IL-17 and 24-hour urinary proteins with a Pvalue of 0.01.Conclusion: SLE cases demonstrated higher levels of serum IL-17, contributing to SLE pathogenesis. However, no statistically significant difference was reported between IL-17 and Lupus nephritis. IL-17 and SLE activity (SLEDAI) did not correlate. A statistically significant positive relation was reported between IL-17 and 24-hour urinary proteins. Additionally, a high statistically significant negative correlation was reported between IL-17 and C3 and C4.","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":"534-543"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current rheumatology reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115733971282065240123075748","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Systemic lupus erythematosus (SLE) is a chronic idiopathic systemic autoimmune disorder with dysregulation of adaptive and innate immune systems. Interleukin (IL)-17 is the prototypical pro-inflammatory cytokine of T helper 17 (Th17) cells. Therefore, it contributes to the pathogenesis of human SLE.

Aim: The aim of the research paper was the evaluation of IL-17 level as a biomarker in the SLE cohort and its relation to disease activity and analysis of IL-17 concentration in patients with lupus nephritis and non-lupus nephritis.

Methods: The research enrolled 45 SLE patients according to Systemic Lupus International Collaborating Clinics Classification Criteria (SLICC), and age and sex-matched. The patients underwent full history, clinical examination, laboratory investigation, and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) calculation.

Results: The mean age ± SD of the participants equaled 32 ± 11 years, and serum IL-17 in SLE cases was statistically significantly high (p < 0.001). No statistically significant correlations were reported between disease activity according to SLEDAI and IL-17. In addition, a statistically significant positive correlation was reported between IL-17 and ESR, and a high statistically significant negative correlation was reported between IL-17 and C3 and C4 (P < 0.001). A statistically significant positive correlation was reported between IL-17 and 24-hour urinary proteins with a Pvalue of 0.01.

Conclusion: SLE cases demonstrated higher levels of serum IL-17, contributing to SLE pathogenesis. However, no statistically significant difference was reported between IL-17 and Lupus nephritis. IL-17 and SLE activity (SLEDAI) did not correlate. A statistically significant positive relation was reported between IL-17 and 24-hour urinary proteins. Additionally, a high statistically significant negative correlation was reported between IL-17 and C3 and C4.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

将埃及系统性红斑狼疮患者的白细胞介素 17 作为疾病活动的生物标志物进行评估

导言系统性红斑狼疮（SLE）是一种慢性特发性全身自身免疫性疾病，其适应性和先天性免疫系统均出现失调。白细胞介素（IL）-17是T辅助细胞17（Th17）的典型促炎细胞因子。目的：该研究论文旨在评估系统性红斑狼疮队列中作为生物标志物的IL-17水平及其与疾病活动的关系，并分析狼疮性肾炎和非狼疮性肾炎患者体内的IL-17浓度：研究根据系统性红斑狼疮国际合作诊所分类标准（SLICC）招募了45名系统性红斑狼疮患者，年龄和性别均匹配。患者接受了全面的病史、临床检查、实验室检查和系统性红斑狼疮疾病活动指数（SLEDAI）计算：结果：参与者的平均年龄（32±11）岁，系统性红斑狼疮患者的血清IL-17明显偏高（P < 0.001）。根据 SLEDAI 计算的疾病活动度与 IL-17 之间没有统计学意义上的相关性。此外，IL-17 与血沉之间存在统计学意义上的显著正相关，IL-17 与 C3 和 C4 之间存在统计学意义上的显著负相关（P < 0.001）。IL-17与24小时尿蛋白呈统计学意义上的正相关，P值为0.01：结论：系统性红斑狼疮病例的血清IL-17水平较高，这与系统性红斑狼疮的发病机制有关。结论：系统性红斑狼疮病例的血清 IL-17 水平较高，有助于系统性红斑狼疮的发病机制，但 IL-17 与狼疮性肾炎之间的差异无统计学意义。IL-17与系统性红斑狼疮的活动性（SLEDAI）不相关。据报告，IL-17 与 24 小时尿蛋白之间存在统计学意义上的正相关。此外，IL-17 与 C3 和 C4 之间存在统计学意义上的高度负相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current rheumatology reviews RHEUMATOLOGY-

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Current Rheumatology Reviews publishes frontier reviews on all the latest advances on rheumatology and its related areas e.g. pharmacology, pathogenesis, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in rheumatology.